Key Highlights

  • TrialKey has signed a services agreement with Paradigm Biopharmaceuticals worth A$25,000 plus GST.
  • The work will independently evaluate design, conduct and analysis of Paradigm's Phase 3 osteoarthritis trial.
  • TrialKey's 14 live services are being converted into contracted project work.
  • The performance figures cited by the company come from internal retrospective testing.

Pathkey.AI Ltd (ASX:PKY) has announced that its Subsidiary TrialKey Pty Ltd has signed a services agreement with Paradigm Biopharmaceuticals Ltd, which is under administration, to provide an independent evaluation of a Phase 3 osteoarthritis study. The agreement, dated 10 November 2026, is worth A$25,000 plus GST. It is a small contract in dollar terms, but the company frames it as the first step in converting its broader trial design offering into paid project work.

Scope of the Paradigm Evaluation

The study in question, PARA_OA_012, tested injectable pentosan polysulfate sodium for knee osteoarthritis. On 23 September 2026, the independent Data Safety Monitoring Board confirmed that the interim efficacy result had not reached the threshold required for the study to continue. Later updates reported differences between United States and rest-of-world results, along with missing assessments and dosing interruptions. The overall interim futility outcome was unchanged.

TrialKey will examine the protocol, statistical analysis plan and de-identified study data to assess potential reasons for the outcome. It will also identify where a different approach to design, conduct or analysis might have affected the findings. The company says its recommendations will be offered to Paradigm for consideration, meaning the outcome of the work depends on the sponsor's response.

How the TrialKey Platform Works

TrialKey uses machine-learning models trained on historical clinical trial data to generate predictive insights, risk assessments and design recommendations. The company combines that historical evidence with information from study documents, with expert review of the outputs. It describes 14 live services covering areas such as identifying study risks, comparing alternative designs and assessing the benefits and costs of a model.

The company reports that recent internal testing showed improved predictions across nine clinical trial outcomes. It is important to note that these results come from retrospective testing conducted internally, not from prospective trials or independent validation.

Commercial Position and Priorities

The company lists further priorities beyond this contract, including delivery of the Paradigm work, additional biotech engagements, and licensing of its technology to clinical research organisations in a pilot form. Additional statistical functions are undergoing testing or validation with clients. The company's stated aim is to move from a broader product offering into a set of contracted engagements.

The commercial scale of the Business is not disclosed in the announcement beyond this single contract. Investors would need further information on Recurring Revenue and the number of active clients to assess the company's progress.

Risks and Matters to Watch

Counterparty risk is present, because the sponsor is under administration and its ability to act on the recommendations is uncertain. The performance claims rest on internal testing, and the company's recommendations on a trial that has already failed its interim threshold may be difficult to validate. Regulatory acceptance of machine-learning tools in trial design is also an area that is still developing.

Final Word

Pathkey.AI's agreement with Paradigm is modest in value but gives TrialKey a contracted client and a live test of its evaluation method on a high-profile failed study. The company's next steps will be measured by whether its recommendations are used, whether further biotech clients sign, and whether the pilot licensing with contract research organisations proceeds. Each of those will provide clearer evidence of commercial traction than the internal test results alone.